About this Journal Submit a Manuscript Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 417017, 8 pages
http://dx.doi.org/10.1155/2012/417017
Research Article

Preventive Treatment with Methylprednisolone Paradoxically Exacerbates Experimental Autoimmune Encephalomyelitis

1Institute for Multiple Sclerosis Research, University of Göttingen and Gemeinnützige Hertie-Stiftung, Waldweg 33, 37073 Göttingen, Germany
2Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD 20892, USA
3Institute of Cellular and Molecular Immunology, University of Göttingen Medical School, Humboldtallee 34, 37073 Göttingen, Germany
4Department of Laboratory Animal Science, Medical School, University of Greifswald, Walther-Rathenau-Straße 49a, 17489 Greifswald, Germany

Received 14 August 2012; Revised 22 October 2012; Accepted 2 November 2012

Academic Editor: Andrew Chan

Copyright © 2012 Simone Wüst et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. M. Milligan, R. Newcombe, and D. A. S. Compston, “A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects,” Journal of Neurology Neurosurgery and Psychiatry, vol. 50, no. 5, pp. 511–516, 1987. View at Scopus
  2. R. L. Oliveri, P. Valentino, C. Russo et al., “Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study,” Neurology, vol. 50, no. 6, pp. 1833–1836, 1998. View at Scopus
  3. B. Fierro, G. Salemi, F. Brighina et al., “A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis,” Acta Neurologica Scandinavica, vol. 105, no. 3, pp. 152–157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Franchin and B. Diamond, “Pulse steroids: how much is enough?” Autoimmunity Reviews, vol. 5, no. 2, pp. 111–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Pozzilli, F. Marinelli, S. Romano, and F. Bagnato, “Corticosteroids treatment,” Journal of the Neurological Sciences, vol. 223, no. 1, pp. 47–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Huscher, K. Thiele, E. Gromnica-Ihle et al., “Dose-related patterns of glucocorticoid-induced side effects,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1119–1124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Steinman and S. S. Zamvil, “How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis,” Annals of Neurology, vol. 60, no. 1, pp. 12–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gold, C. Linington, and H. Lassmann, “Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research,” Brain, vol. 129, no. 8, pp. 1953–1971, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Lassmann, “Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models,” Experimental Neurology, vol. 225, no. 1, pp. 2–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Wüst, J. Van Den Brandt, D. Tischner et al., “Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 180, no. 12, pp. 8434–8443, 2008. View at Scopus
  11. S. Wüst, D. Tischner, M. John et al., “Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis,” PLoS ONE, vol. 4, no. 12, Article ID e8202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Ž. Miljković, M. Momčilović, D. Miljković, and M. Mostarica-Stojković, “Methylprednisolone inhibits IFN-γ and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis,” Journal of Neuroinflammation, vol. 6, article 37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Schweingruber, A. Haine, K. Tiede et al., “Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 187, pp. 4310–4318, 2011.
  14. H. Luche, O. Weber, T. N. Rao, C. Blum, and H. J. Fehling, “Faithful activation of an extra-bright red fluorescent protein in “knock-in” cre-reporter mice ideally suited for lineage tracing studies,” European Journal of Immunology, vol. 37, no. 1, pp. 43–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Lühder, C. Chambers, J. P. Allison, C. Benoist, and D. Mathis, “Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12204–12209, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. de Seze, M. Chapelotte, S. Delalande, D. Ferriby, T. Stojkovic, and P. Vermersch, “Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 5, pp. 596–597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Magraner, F. Coret, A. Navarré et al., “Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study,” Journal of Neurology, vol. 258, no. 10, pp. 1805–1811, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Edan, G. Comi, E. Le Page, E. Leray, M. A. Rocca, and M. Filippi, “Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, pp. 1344–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. E. J. Fox, H. C. Sullivan, S. K. Gazda et al., “A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis,” European Journal of Neurology, vol. 19, pp. 307–311, 2012.
  20. J. Schmidt, J. M. Metselaar, M. H. M. Wauben, K. V. Toyka, G. Storm, and R. Gold, “Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis,” Brain, vol. 126, no. 8, pp. 1895–1904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Linker, C. Weller, F. Lühder et al., “Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations,” Experimental Neurology, vol. 211, no. 2, pp. 397–406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Chan, E. J. Ban, K. H. Chun et al., “Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis,” Autoimmunity, vol. 41, no. 5, pp. 405–413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. S. Wei, M. F. Hong, Q. X. Su et al., “Super-high-dose methylprednisolone does not improve efficacy or induce glucocorticoid resistance in experimental allergic encephalomyelitis,” NeuroImmunomodulation, vol. 18, no. 1, pp. 28–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Schmidt, R. Gold, L. Schönrock, U. K. Zettl, H. P. Hartung, and K. V. Toyka, “T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy,” Brain, vol. 123, no. 7, pp. 1431–1441, 2000. View at Scopus
  25. G. De Camargo Furtado, D. Olivares-Villagómez, M. A. Curotto De Lafaille, A. K. Wensky, J. A. Latkowski, and J. J. Lafaille, “Regulatory T cells in spontaneous autoimmune encephalomyelitis,” Immunological Reviews, vol. 182, pp. 122–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. O'Connor and S. M. Anderton, “Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease,” Journal of Neuroimmunology, vol. 193, no. 1-2, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Steiner, T. Brenner, R. Mizrachi-Kol, and O. Abramsky, “Development of experimental allergic encephalomyelitis during steroid administration. Outcome of neurological immune-mediated disorders under immunosuppressive therapy,” Israel Journal of Medical Sciences, vol. 27, no. 7, pp. 365–368, 1991. View at Scopus
  28. A. K. Artemiadis, M. C. Anagnostouli, and E. C. Alexopoulos, “Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review,” Neuroepidemiology, vol. 36, no. 2, pp. 109–120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. E. R. De Kloet, M. Joëls, and F. Holsboer, “Stress and the brain: from adaptation to disease,” Nature Reviews Neuroscience, vol. 6, no. 6, pp. 463–475, 2005. View at Publisher · View at Google Scholar · View at Scopus